Current Report Filing (8-k)
May 23 2013 - 4:31PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date Of Report (Date Of Earliest Event Reported):
May 23, 2013
NORTHWEST BIOTHERAPEUTICS, INC. |
(Exact Name of Registrant as Specified in Its Charter) |
Delaware |
|
0-33393 |
|
94-3306718 |
(State Or Other Jurisdiction Of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
4800 Montgomery Lane, Suite 800, Bethesda,
MD 20814
(Address Of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including
Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On May 23, 2013, Northwest Biotherapeutics,
Inc. (the “Company”) issued a press release announcing that it will use its exhibit at this year’s American Society
of Clinical Oncology (ASCO) meeting in Chicago to highlight its leadership role in immune therapy. A copy of the press release
is included as Exhibit 99.1 to this Current Report on Form 8-K.
The information disclosed under this Item 8.01,
including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or
other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Press Release of Northwest Biotherapeutics, Inc. dated
May 23, 2013.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC |
|
|
|
Dated: May 23, 2013 |
By: |
/s/ Linda Powers |
|
|
Name: Linda Powers |
|
|
Title: Chief Executive Officer and Chairman |
|
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2023 to Aug 2024